China drug licensing deals surge nearly 10-fold in value since 2021
Source: SeekingAlpha
2026-02-19 13:31:04 ET
More on AbbVie, AstraZeneca PLC, etc.
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- Pfizer: The Rebound Looks Unsustainable
- AbbVie: Dominating Immunology While Building Oncology Upside
- Merck posts new Enflonsia RSV data in infants
- Merck reports positive phase 3 second-season RSV data for ENFLONSIA
Read the full article on Seeking Alpha
For further details see:
China drug licensing deals surge nearly 10-fold in value since 2021
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
0.21% G/L:
$228.2209 Last:
2,045,501 Volume:
$226.05 Open:
ABBV Latest News
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
